Aura Biosciences, Inc. (AURA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.34-4.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · AURA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
AURA — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition. On August 11, 2026, (the “Effective Date”), Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc…
Why it matters: The cash plan funds CoMpass and other eye cancer studies. A shorter runway could force new financing or program cuts.
Worry ifA later company update still says cash can fund operations into 1H 2029. No new financing is announced.
Less concerning ifAura moves its cash runway estimate to before 1H 2029 or announces funding for planned work.
Why it matters: Aura plans to cut its workforce by about 20% and focus on eye cancer. The update can show if the plan is done and costs stay controlled.
Watch forThe November 5 update says the restructuring is nearly complete. Costs stay near the stated $2.9 million to $3.2 million range, and cash runway remains into 1H 2029.
Also watch forThe update reports costs above $3.2 million, delayed restructuring, or a shorter cash runway than 1H 2029.
Why it matters: Aura plans to add resources to both programs. Clear study plans and useful data could broaden its eye cancer work beyond CoMpass.
Supportive ifBy Q1 2027, Aura gives plans to finish studies of choroid metastases and ocular surface cancers. The plans include timelines and data goals.
Worry ifThe Q1 2027 update is delayed, or Aura reports a pause or cut to either program.
Why it matters: The Phase 3 trial tests bel-sar against sham in early choroidal melanoma. A positive result could support a path to FDA review.
Supportive ifTopline data meet the 15-month primary endpoint, with results that support bel-sar over sham.
Worry ifTopline data miss the primary endpoint or do not show a clear benefit over sham.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$209 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $435 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,258 loss on $10,000 · 32.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.